Fusion Antibodies: results underwhelm
Fusion Antibodies (LON: FAB), specialists in pre-clinical antibody discovery, for both therapeutic drug and diagnostic applications, underwhelmed with its interim results for the six months ending 30 September 2020, at least for a business with its high rating – the current market capitalisation is £29m.
Revenues rose 8.5% of £1.90m with losses remaining stable at £0.47m.
They expanded their R&D programme in the period by 50% to £271k to include a COVID-19 target…
Sign up and read the full article
Register to continue reading our content.
Get FREE access now
Already a member? Login
Previous article
Next article
More on Advanced Medical Solutions
18/07/2025 · Company Insights
News covered here includes our assessment of a positive trading update from a company benefitting from…
19/03/2025 · Company Insights
There are plenty of excellent results from AIM covered here, but we are surprised a pawnbroker…
More on Argentex Group PLC
24/04/2025 · Company Insights
AIM investors returning from their Easter break were ‘welcomed’ back with dramatic news from one of…
02/04/2025 · Company Insights
A new management team is executing its plan to accelerate growth in this expert in currency risk management…
More on Frasers Group
06/12/2024 · Company Insights
News covered here incudes our assessment of results from a lowly valued UK fund manager, whose…
01/10/2024 · Company Insights
One of AIM’s largest companies seems inclined to accept a private equity funded offer, with an…
More on Fusion Antibodies PLC
20/11/2020 · Company Insights
Mike Ashley’s Frasers has upped its stake in Mulberry and is obliged to contemplate a full…
28/04/2020 · Company Insights
Announcements included an update from from Burford Capital, which saw its shares bounce strongly, but we still…
More Company Insights
Cash and asset-rich Bonkers Bargain better-placed than rivals
Excellent results despite the sector challenges
Another derisory offer for a UK small cap
More on Advanced Medical Solutions
More on Argentex Group PLC
More on Frasers Group
More on Fusion Antibodies PLC
More Company Insights